Good news | ReCOV, a new adjuvant of Ruike Biology, has been authorized by Mongolia for emergency use
2023/03/28
Ruike Biology (stock code: 02179. HK) recently announced that, according to the Mongolian law on the prevention and fight against the novel coronavirus (SARS CoV-2) epidemic, the Mongolian Minister of Health Order A106 and the resolution of the meeting of the Mongolian countrymen Drug Commission granted Ruike Biology the emergency use authorization of the recombinant two-component COVID-19 vaccine ReCOV.
This product is jointly designed and developed by Ruike Biology and Professor Wang Xiangxi of Institute of Biophysics, Chinese Academy of Sciences. It is the first new adjuvant recombinant subunit COVID-19 vaccine independently developed in China and approved overseas. The preclinical safety evaluation of this vaccine was completed by Shandong Xinbo Pharmaceutical Research Co., Ltd.
New adjuvants have become a key factor in the success of innovative vaccine research and development in China. ReCOV is a recombinant COVID-19 vaccine developed for the core technology platform of Ruike Biology, which comprehensively uses new adjuvants, protein engineering, immune evaluation, etc. Its adjuvants use the independently developed BFA03 new adjuvant. Ruike Biotechnology has conducted multiple post clinical studies on ReCOV in China, the Philippines, the United Arab Emirates, Nepal, and Russia.
Research shows that ReCOV has overall good safety, with mild adverse reactions and no serious vaccine related adverse events found. Especially in clinical studies with Pfizer mRNA vaccine as a positive control, sequential reinforcement of ReCOV in populations previously vaccinated with inactivated vaccines can induce persistent and extensive cross neutralizing antibodies against multiple Omicron variants such as BF.7, BA. 5, BA. 2.75, BA. 2, etc. The neutralizing antibody levels in each subgroup were superior to those of Pfizer mRNA vaccine (with statistical differences).
Shandong Xinbo Pharmaceutical Research Co., Ltd. is committed to the preclinical safety evaluation of biopharmaceuticals, traditional Chinese medicine, chemical drugs, and medical devices, providing standardized and comprehensive preclinical solutions for innovative pharmaceutical enterprises and assisting in the drug development process.
This product is jointly designed and developed by Ruike Biology and Professor Wang Xiangxi of Institute of Biophysics, Chinese Academy of Sciences. It is the first new adjuvant recombinant subunit COVID-19 vaccine independently developed in China and approved overseas. The preclinical safety evaluation of this vaccine was completed by Shandong Xinbo Pharmaceutical Research Co., Ltd.
New adjuvants have become a key factor in the success of innovative vaccine research and development in China. ReCOV is a recombinant COVID-19 vaccine developed for the core technology platform of Ruike Biology, which comprehensively uses new adjuvants, protein engineering, immune evaluation, etc. Its adjuvants use the independently developed BFA03 new adjuvant. Ruike Biotechnology has conducted multiple post clinical studies on ReCOV in China, the Philippines, the United Arab Emirates, Nepal, and Russia.
Research shows that ReCOV has overall good safety, with mild adverse reactions and no serious vaccine related adverse events found. Especially in clinical studies with Pfizer mRNA vaccine as a positive control, sequential reinforcement of ReCOV in populations previously vaccinated with inactivated vaccines can induce persistent and extensive cross neutralizing antibodies against multiple Omicron variants such as BF.7, BA. 5, BA. 2.75, BA. 2, etc. The neutralizing antibody levels in each subgroup were superior to those of Pfizer mRNA vaccine (with statistical differences).
Shandong Xinbo Pharmaceutical Research Co., Ltd. is committed to the preclinical safety evaluation of biopharmaceuticals, traditional Chinese medicine, chemical drugs, and medical devices, providing standardized and comprehensive preclinical solutions for innovative pharmaceutical enterprises and assisting in the drug development process.
